Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Tirzepatide
Clinical
FDA-approved (specific use)
Summary
Dual GIP/GLP-1 receptor agonist with strong clinical weight-loss and glycemic outcomes.
Categories
Metabolic & Body Comp
Mechanism
Agonizes both GIP and GLP-1 receptors, enhancing insulin response, reducing appetite, and improving metabolic markers.
Half-life
~5 days (weekly dosing)
Routes
Subcutaneous injection
Legal / access
Prescription-only approved medicines exist. Gray-market research vials are not equivalent.
Key risks
- GI upset (nausea, diarrhea, constipation)
- Injection-site reactions
- Gallbladder risk
- Muscle loss without training stimulus
Common claims
- Higher average weight loss than single GLP-1s
- Stronger food-noise suppression
- Improved lab markers under care
Select peptide B